Welcome to investors
Atticus Medical is a biotechnology company developing new medicines for diseases that affect disadvantaged communities.
INVESTMENT IMPACT
A unique opportunity for global impact
Direct impact
Over 200 million people with scabies, headlice and demodex infestation would have access to a better medicine.
Indirect impact
Our medicines are expected to reduce stigma, improve education outcomes and enhance the quality of life for both patients and their families.
Use of funds
Atticus Medical is working toward three key milestones
Milestone 1
Regulatory approval of AM-2 for the treatment of scabies.
Milestone 2
Selection of the most appropriate doses of AM-3 and AM-4 for treatment of demodex blepharitis and headlice.
Milestone 3
Improving access to moxidectin by making it commercially available in major markets.